Alterations in microRNA expression are very common in various human cancers and have shown significant potential role in cancer management. In this study, microRNA expression signatures have been identified for HCC classification and prognosis. A 30-miRNA signature was developed to discriminate HCCs from corresponding non-cancerous liver tissues in the training set. A 20-miRNA signature, in which each miRNA was found significantly associated with the survival of HCC patient, was established for predicting survival in the training set.
INTRODUCTION
MicroRNA (miRNA) is a small non-coding RNA of about 22-nt that play important roles in posttranscriptional gene regulation (1) . By base-pairing with the 3' untranslated regions (3'UTRs) of target messenger RNAs (mRNAs), miRNA is capable of degrading target mRNA or down-regulating mRNA translation (2) . Since the discovery of the first miRNA lin-4 in 1993 (3, 4) , thousands of miRNAs have been identified in human, animals, plants, and viruses by molecular cloning, sequencing and computational approaches (5, 6) . miRNAs are now widely recognized to play important roles in the control of developmental and physiological processes, especially in developmental timing, cell death, cell proliferation, haematopoiesis and patterning of the nervous system (7) . During cancer development and progression, miRNA can function as tumor suppressor or oncogene (8) (9) (10) (11) . As such, they are often referred to as Oncomirs (11) .
Many studies indicate that miRNA expression signatures or profiles can serve as diagnosis and prognosis predictors for various tumors (12) (13) (14) (15) . miRNA profiles have been shown to be more accurate for classification of cancers compared with mRNA profiles (14) . Several studies on miRNA expression profiles in HCCs revealed the extensive correlations between miRNA expression and HCC development, progression and therapy (16, 17) . However, only a limited number of miRNA species were analyzed detected in these studies due to the small number of known miRNA available at that time.
In this study, we analyzed the miRNA expression profiles in 166 HCC patients from South China using a custom microarray consisting of probes for 683 miRNAs, which is much larger than any of the previous studies. As a result, we identified a 30-microRNA signature for classifying HCC and non-cancerous liver (NC) and a 20-miRNA signature for predicting HCC survival in a training set, and validated them in a test set and an independent cohort. The patients were randomly assigned into a training set (n=60) and test set (n=50). Another 56 patients subjected to hepatectomy during 2001 to 2003 in the same center were used as the independent set. The HCC tissues were pathologically confirmed by two pathologists. All of patients received a radical hepatectomy and no distance metastasis was found before surgery.
The clinical characteristics of all patients in the 3 sets were summarized in Table 1 . The follow-up times ranged from 1 to 58 months with a median time of 39 months for 110 patients and from 1 to 81 month with a median time of 28 months for 56 patients, respectively.
The overall survival (OS) time was calculated from the date of surgery to the date of death, and disease-free survival (DFS) time from the date of surgery to the first relapse or distant metastasis or death. The data of patient survival was presented in Table S1 .
Both HCC and corresponding adjacent NC (more than 2 cm away from the HCC) were sampled. Fresh tissues were immediately immersed in RNAlater (Ambion, Inc., USA) after surgical resection, stored at 4℃ overnight, and then frozen at -80℃ until use. Total RNA was extracted using the TRIzol reagent (Invitrogen, USA) according to the manufacturer's instructions.
This study was reviewed and approved by the Committee for the Conduct of Human
Research of the Sun Yat-Sen University Cancer Center. Written informed consent was obtained from each HCC patient. None of the patients had received any other therapies such as chemoembolization or chemotherapy before surgery.
MicroRNA microarray fabrication, RNA labeling and hybridization
Research. Microarray fabrication was carried out as described by Wang HY et al (18) , and probe design and RNA labeling were performed according to published protocols with minor modifications (19) . Briefly, all of the human microRNAs (Release 12) in the miRBase (20) were used to design the probes. With the principles described by Wang H (19), 683 probes for miRNAs were successfully designed for the microarray. For fabrication of microarray, the probes (40 μM final concentration) mixed with printing buffer were printed onto slides in duplicate using SmartArrayer™ 136 printer (CapitalBio Inc, Beijing, China). The quality of microarray was tested using two control RNA samples to do hybridization for every batch of microarrays and the correlation among the different microarray batches was analyzed. The correlation analysis showed that the correlation coefficient was more than 95%, indicating that the differences between the batches of microarrays were in the acceptable range. During the labeling reaction, 2.5 μg of total RNA was employed with 100 nmol/L of pCp-DY647 or pCp-DY547 (Dharmacon, Lafayette, CO, USA) and 15 Units of T4 RNA ligase (USB, Cleveland, Oh, USA) in a total reaction volume of 20 µL at 16 ℃ overnight. Labeled RNAs from paired HCC and NC were mixed and hybridized to the array with a 2×hybridization solution (final concentration: 5× Denhart's solution, 0.5% SDS, 5× SSC) in a Hybridization Chamber (Corning Inc, Corning, NY, USA) at 46 ℃ for 12 to 16 hours. After washing, microarray was scanned with a LuxScan™ 10K Microarray Scanner (CapitalBio Inc, Beijing, China) at PMT 800-900. Scanned images were gridded using the GenPix Pro 6.0 software (Axon Instruments, Foster City, CA, U.S.A.).
Quantitative real time RT-PCR
The reverse transcription (RT) was performed with 2 μg of total RNA isolated from HCC or corresponding NC tissues, 5 nM of Bulge-Loop™ miRNA RT specific primers (RiboBio 
Data process and statistical analyses
Microarray raw data preprocessing included: local background subtraction, averaging of intensities of duplicated probes, quantile normalization across multiple arrays, log 2 transformation of expression levels. Only the miRNAs with expression in more than 15 % of samples were subjected to further statistical analysis. This normalized microarray data have been deposited into the Gene Expression Omnibus (GEO) Public Database at the National Center for Biotechnology Information, and the accession number is GSE31384. performed in the test set and the independent cohort ( Figure S1B and S1C). The Predicted Classes and Predicted Posterior Probabilities were listed in table S2. In the test set, the accuracy, sensitivity and specificity for distinguishing between HCC and NC were 97%, 100% and 94%, respectively; in the independent cohort, those were 90%, 94% and 88%, respectively. This result suggested that the 30-miRNA signature for distinguishing between HCC and NC was robust.
RESULTS

Identification
In addition, we analyzed the relationship of miRNA expression with cirrhosis, pathological grade and clinical stage in whole cohort and found some differential expression of miRNAs between these characteristics using the criteria of fold change > 1.5 and p-value < 0.05 (Table S3) .
Real time RT-PCR validation of miRNA expression levels detected by microarray
To validate the miRNA expression level detected by microarray, we carried out qRT-PCR for 2 up-regulated miRNAs (mir-17 and mir-21) and 2 down-regulated ones (mir-269-5p and mir-625*) in 60 paired HCC and NC samples from the training set. In the qRT-PCR assay, U6 gene was used as an endogenous control. The results showed that the expression levels of the four miRNAs detected by qRT-PCR were significantly different between HCCs and NC tissues as indicated by paired student's t-test (all P<0.05, Figure 2A ), and strongly correlated with the microarray data ( Figure 2B ). These results demonstrate that microRNA levels detected by microarray are reliable and can be used for the further analysis.
Identification of 20 miRNAs associated with survival in the training Set
The microarray raw data in the training set were normalized and transformed into a log2 ratio of HCC to NC by BRB-ArrayTools, and then miRNAs with expression in less than 15% of samples and change in expression less than 1.5-fold were filtered (23, 24) . To identify a miRNA signature correlated with patient's survival, the relationship between miRNA expression levels and patients' survival was assessed in the training set by fitting Cox proportional hazards models using BRB-ArrayTools software, and miRNAs were chosen by the criteria of p value < 0.1. Then different combinations of miRNAs were tested for predicting HCC survival. In this way, a best combination (20 miRNA) was selected to achieve the best prediction of survival of HCC patients. A simple formula for computing prognostic index was established from the 20 miRNAs: ∑ i w i x i -0.375, where w i and x i are the weight and logged gene expression level for the i-th gene, and the weight of each miRNA are shown in Table 3 . Of the 20 miRNAs, 6 microRNAs were risk factors that were defined as those with hazard ratio for death > 1, and the other 14 microRNAs were protective factors that were defined as those with hazard ratio for death < 1 (Table 3) . With this formula, each patient had a prognostic index and the median of prognostic index for all patients in training set was -0.090. Patients were assigned to a high-risk group if their prognostic index was larger than -0.090, and were assigned to a low-risk group if their prognostic index was equal to or less than -0.090.
Correlation between the 20-miRNA signature and patient survival in the training Set
Using the 50th percentile of the 20-miRNA prognostic index as a cutoff point (-0.090), 60 patients in the training set were separated into a high-risk (high index) subgroup or a low-risk (low index) subgroup according to their prognostic index. There were 30 patients in high-risk group with a 3-year survival rate of 35.3% and 30 in the low-risk group with a 3-year survival rate of 92.6%. Kaplan-Meier survival analysis of the patients in the two subgroups revealed that both overall survival (OS) rate and disease-free survival (DFS) rate in the high-risk group were significantly lower than those in the low-risk group (P<0.001 and P<0.001, respectively, see Figure 3A) . To validate the 20-miRNA signature for predicting survival of HCC patients, 50 patients in the test set were classified into a high-risk subgroup and a low-risk subgroup based on the same Cox proportional hazards model and cutoff point, which were obtained from the training set. Kaplan-Meier survival analysis on the patients with high-risk (n=23) and low-risk (n=27) also was conducted as described for the training set. As expected, the OS and DFS rate of the patients with high-risk were markedly poorer than those of patients with low-risk (P =0.033, P =0.039, respectively, Figure 3B ). Kaplan-Meier survival analysis showed similar results to those in the training set and test set.
The OS and DFS of high-risk group were significantly worse than those of the low-risk group (P = 0.033 and P = 0.040, respectively, Figure 3C ).
To directly demonstrate the relationship between the 20-miRNA prognostic index and survival, we plotted the prognostic index and survival status of all patients in training and test sets ( Figure S2 ). In this plot, patients with low-risk scores had much fewer deaths than those with high-risk score. Likewise, similar results were found in the training set, test set and independent cohort ( Figure S3A , Figure S3B and Figure S3C (Table 4) . Cox regression analysis on the score of the 20-miRNA signature indicated that the patients with high-risk had a significant higher hazard ratio for tumor-related death (HR=2.75) compared with those with low risk. In addition, we performed univariate and multivariate Cox regression analysis on the patients in the three sets separately (Table S4 ) and combination of two sets (Table S5 ). The results were generally consistent with those in the whole cohort.
DISCUSSION
In this study, we fabricated a custom microarray containing 683 microRNAs to detect miRNA profiles in HCC patients from Southern China. Although there had been some reported miRNA profiling studies on HCC, the total number of human miRNA species in those studies was very limited ( about 300 at most) (25, 26) . This is the first study in which a microarray consisting of 683 miRNAs has been used in profiling 166 HCCs. With this microarray, a 30-miRNA signature for discriminating HCCs from NC samples was established in the training set and validated in the test and independent set. This result shows that the signature identified from the training set is highly reproducible in the test and independent sets despite some heterogeneity in the latter set. result provides an independent validation of our result. With regard to the correct classification rate, our 30-miRNA signature was 99.2% accuracy for distinguishing HCC from NC in training set, which was verified in the test and independent sets. The accuracy of our signature was higher than all previously reported miRNA signatures.
In addition, there are 11 unique miRNAs (miR-296-1, miR-486-5p, miR-516a-5p, miR-612, miR-625*, miR-634, miR-675, miR-766, miR-933 and miR-940) in our 30-miRNA signature, which have not been reported in HCC by others because many of them were only recently identified and made available in the public database, and the number of miRNAs included in our study are much more than those in previous studies. The studies on miRNA differential expression between HCC and NC suggested that miRNA expression profile might be a potential diagnostic tool in HCC clinical practice and provides a clue for exploring molecular mechanism of hepatocarcinogenesis and discovering new molecular targets for HCC therapy.
With the custom microarray, we also identify a 20-miRNA signature that is significantly discrepancy is that the number of miRNAs in our study was nearly 4 times more than that in Jiang's study. In yet another HCC miRNA profiling study using a microarray containing about 225 human miRNA probes, Budhu et al identified a metastasis-related 20-miRNA signature (30). In comparison with the miRNAs in our survival 20-miRNA signature, only one miRNA (has-miR-15a) is common even though the metastasis-related signature was also reported to be associated with outcome of HCC. Six miRNAs of our 20-miRNA signature were identified recently and deposited into the miRBase database and not included in Budhu's microarray.
Thus, our 20-miRNA signature appears to be more representative and comprehensive than other signatures.
In univariate Cox analysis, our 20-miRNA signature was a significant predictor in the training, test and independent sets (Table S4) , respectively. In multivariate Cox analysis, the 20-miRNA signature was a significant independent predictor in training set and a marginally significant independent predictor in test set, but not an independent predictor in independent cohort (Table S4) . However, when combined with the test set and independent cohort, the signature was a significant independent predictor with multivariate Cox analysis (Table S5 ).
These results suggest that this signature should be also an independent predictor in the test set or independent cohort if the sample size is increased.
In the present study, HBeAg was shown to be an independent predictor for survival of HCC patients, which is not often reported in the published literature. HBV infection is a major cause of hepatocellular carcinoma in some areas, especially in China, and HBeAg is a marker of active HBV replication and infection, which aggravates the impaired liver function of HCC patients. Liver function status is an important predictor of HCC survival and one of the main factors of the HCC clinical staging system. Hence, it is possible that HBeAg is associated with HCC survival. Some studies on HCC patients with HBV infection indicate that HBeAg is an independent prognostic factor or correlated with HCC survival (31, 32). Furthermore, a lot of studies indicate that HBV infection is a predictive factor for HCC survival (33, 34).
Research. 
In conclusion, we used a large comprehensive set of miRNAs to identify a new 30-miRNA signature that can discriminate HCC tissues from NC tissues and a novel 20- 
